Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis
about
The Contribution of Peroxisome Proliferator-Activated Receptor Gamma to Cutaneous Wound HealingFibroblasts in fibrosis: novel roles and mediatorsA synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responsesAlzPathway: a comprehensive map of signaling pathways of Alzheimer's disease.Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts.Pathogenesis of Systemic Sclerosis.Effect of a high fat, high sucrose diet on the promotion of non-alcoholic fatty liver disease in male rats: the ameliorative role of three natural compounds.Regulation of Matrix Remodeling by Peroxisome Proliferator-Activated Receptor-γ: A Novel Link Between Metabolism and Fibrogenesis.Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as biomarker?Purinergic signaling in scarring.The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-γ and CB2 pathwaysThe adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy.Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy.Hanging in the balance: endogenous anti-inflammatory mechanisms in tissue repair and fibrosis.Scleroderma therapy: clinical overview of current trends and future perspective.Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development.Novel investigational agents for the treatment of scleroderma.The role of PPARγ-mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology.The Role of PPAR Gamma in Systemic Sclerosis.MFAP5 is related to obesity-associated adipose tissue and extracellular matrix remodeling and inflammation.Stromal and immune cells in gut fibrosis: the myofibroblast and the scarface.Loss of PPARγ expression by fibroblasts enhances dermal wound closure.Serum adipokines levels in patients with systemic sclerosis: A meta-analysis.Candidate SNP Markers of Familial and Sporadic Alzheimer's Diseases Are Predicted by a Significant Change in the Affinity of TATA-Binding Protein for Human Gene Promoters.Ajulemic acid exerts potent anti-fibrotic effect during the fibrogenic phase of bleomycin lung.Interactions between TGF-β1, canonical WNT/β-catenin pathway and PPAR γ in radiation-induced fibrosis.The nuclear receptor constitutive androstane receptor/NR1I3 enhances the profibrotic effects of transforming growth factor β and contributes to the development of experimental dermal fibrosis.MicroRNA-130b regulates scleroderma fibrosis by targeting peroxisome proliferator-activated receptor γ.Epoxygenase inactivation exacerbates diet and aging-associated metabolic dysfunction resulting from impaired adipogenesis.
P2860
Q26865930-D426022A-8ACB-4726-9BD0-F44D14F271B0Q26998508-6257531E-0116-4DFB-8BFB-9F202129E5D2Q33637862-36D29C71-67A9-4245-9B1D-4C6FE6B0A2F9Q34286579-5E8C0C86-6895-40F6-9AE9-6031097F6462Q34995163-F28FA151-E353-4C81-9F8D-7EC5F8D1C22CQ35693212-B47988E3-2C2E-4758-9723-835CE3D23CCEQ35903361-DF145BB9-BBF9-4D77-A0D5-38FC65C98F09Q36093802-AC789A99-5064-4C3C-82FC-540198E78B33Q36245922-2EB6507E-35A9-449D-B534-8A5A20DD4F36Q36385326-0D50FDFC-8FB0-4020-B220-95E63CF32976Q36591533-D1257FD3-6401-444B-B21A-2FE3BBBC7282Q36633255-73B22F01-D37A-4CD4-84FD-05CD22B3C5E5Q37638268-F5A5C1AA-1DC5-448F-A478-2DF2D0D093B0Q37721063-AAB46AA8-0CA8-4E88-B31D-7B8D9C077253Q38046124-C0B48697-A906-4CF7-9294-D9B8650830B7Q38046467-CE318B79-318D-4AC1-A3BA-A9C8E74C2DC1Q38156227-1CC61763-1AAD-4462-93D7-F0CEF9A92C94Q38164818-D37A4A8A-F8E9-4EEE-9246-6D14B9FE5F3AQ38341507-5695D851-7BDC-419F-8661-5F9E22A6FD22Q38524619-8033FE23-6F88-4A87-BB61-6E70E508784AQ38866293-1A923176-2640-4CEB-8D50-B0A5A242931EQ39401444-36B387DA-B0F4-4CD4-B46D-EF99B4CD142EQ39629362-4FB722E2-43BF-494F-8199-14974988E406Q39671627-927F84DF-309A-4098-B512-C70E8CCB2588Q41062049-B8E1E906-410F-449A-99F8-F1ABF0BA46E4Q41139723-42EC6509-8D95-419B-A893-99C025E0D521Q47109594-D3044BF1-6AD8-478E-91A6-AB815D21BB32Q50050279-5C12D923-AA9E-4421-B04D-DDCAF4EBFC7EQ53651758-E3F219E0-A852-4066-9F31-F509CAB1FFEAQ55317545-D1899C15-7DE2-4299-83F4-3FA0958FA566
P2860
Peroxisome proliferator-activated receptor γ: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@ast
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@en
type
label
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@ast
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@en
prefLabel
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@ast
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@en
P2093
P2860
P1476
Peroxisome proliferator-activa ...... c target in systemic sclerosis
@en
P2093
John Varga
Swati Bhattacharyya
P2860
P304
P356
10.1097/BOR.0B013E32833DE1A7
P577
2010-11-01T00:00:00Z